Haleon (LON:HLN) Stock Price Expected to Rise, Berenberg Bank Analyst Says

Haleon (LON:HLN) had its target price boosted by investment analysts at Berenberg Bank from GBX 512 to GBX 514 in a report issued on Wednesday,London Stock Exchange reports. The brokerage presently has a “buy” rating on the stock. Berenberg Bank’s target price suggests a potential upside of 40.98% from the stock’s previous close.

A number of other brokerages have also recently commented on HLN. Royal Bank Of Canada restated a “sector perform” rating and set a GBX 370 price objective on shares of Haleon in a research note on Thursday, April 30th. JPMorgan Chase & Co. dropped their target price on Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a report on Thursday, June 25th. Jefferies Financial Group reissued a “buy” rating and set a GBX 400 price target on shares of Haleon in a research report on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Haleon from GBX 325 to GBX 335 and gave the stock a “sell” rating in a report on Friday, July 31st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of GBX 395.67.

Haleon Stock Performance

Shares of HLN stock opened at GBX 364.60 on Wednesday. The company has a current ratio of 0.92, a quick ratio of 0.93 and a debt-to-equity ratio of 52.26. The company has a market cap of £32.11 billion, a PE ratio of 19.71, a P/E/G ratio of 1.49 and a beta of 0.24. The company’s fifty day simple moving average is GBX 350.52 and its 200-day simple moving average is GBX 363.02. Haleon has a 52 week low of GBX 317.80 and a 52 week high of GBX 416.10.

Haleon (LON:HLN) last announced its quarterly earnings results on Thursday, July 30th. The company reported GBX 8.60 earnings per share for the quarter. Haleon had a net margin of 15.11% and a return on equity of 10.30%. As a group, equities research analysts anticipate that Haleon will post 19.5033282 EPS for the current year.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.